{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-324917","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2026-07-30T11:38:04+00:00","discovered_at":"2026-07-30T11:40:00.402309+00:00","generated_at":"2026-07-30T11:40:06.527358+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Wave Life Sciences Q2 net loss $69.4M; WVE-007 Phase 2a dosing underway; FDA meeting for WVE-006","bullets":["Net loss $69.4M vs $50.5M YoY; revenue $2.3M vs $8.7M; cash $490.6M, runway into 3Q 2028.","WVE-007 (obesity) Phase 2a multidose dosing underway in BMI 35-50; combo/maintenance trials on track for 2H 2026.","FDA meeting scheduled for end of summer 2026 to discuss accelerated approval for WVE-006 (AATD).","WVE-008 (PNPLA3) CTA filing on track for 2H 2026; partnering discussions for HD and DMD programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-324917","json":"https://secwatch.observer/filing/0001193125-26-324917.json","markdown":"https://secwatch.observer/filing/0001193125-26-324917.md","text":"https://secwatch.observer/filing/0001193125-26-324917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/0001193125-26-324917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/d177737d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T11:40:06.527358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}